Compare VERA & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERA | XERS |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2021 | 2021 |
| Metric | VERA | XERS |
|---|---|---|
| Price | $29.79 | $10.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 7 |
| Target Price | ★ $74.20 | $12.86 |
| AVG Volume (30 Days) | 1.6M | ★ 2.5M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | N/A | $32.91 |
| Revenue Next Year | $841.44 | $23.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $23.05 | $5.25 |
| 52 Week High | $56.05 | $11.42 |
| Indicator | VERA | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 56.97 |
| Support Level | $26.38 | $9.73 |
| Resistance Level | $36.95 | $10.60 |
| Average True Range (ATR) | 1.58 | 0.48 |
| MACD | 0.19 | -0.06 |
| Stochastic Oscillator | 58.65 | 41.25 |
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.